These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32012897)

  • 41. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD).
    Sheikh MA; Malik YS; Xing Z; Guo Z; Tian H; Zhu X; Chen X
    Acta Biomater; 2017 May; 54():58-68. PubMed ID: 28025049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of lentivirus-mediated PSPN genetic engineering bone marrow mesenchymal stem cells on Parkinson's disease rat model.
    Yin X; Xu H; Jiang Y; Deng W; Wu Z; Xiang H; Sun P; Xie J
    PLoS One; 2014; 9(8):e105118. PubMed ID: 25118697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GDNF Promotes Survival and Therapeutic Efficacy of Human Adipose-Derived Mesenchymal Stem Cells in a Mouse Model of Parkinson's Disease.
    Sun S; Zhang Q; Li M; Gao P; Huang K; Beejadhursing R; Jiang W; Lei T; Zhu M; Shu K
    Cell Transplant; 2020; 29():963689720908512. PubMed ID: 32292068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
    Cerri S; Greco R; Levandis G; Ghezzi C; Mangione AS; Fuzzati-Armentero MT; Bonizzi A; Avanzini MA; Maccario R; Blandini F
    Stem Cells Transl Med; 2015 Sep; 4(9):1073-85. PubMed ID: 26198165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PARKIN overexpression in human mesenchymal stromal cells from Wharton's jelly suppresses 6-hydroxydopamine-induced apoptosis: Potential therapeutic strategy in Parkinson's disease.
    Bonilla-Porras AR; Arevalo-Arbelaez A; Alzate-Restrepo JF; Velez-Pardo C; Jimenez-Del-Rio M
    Cytotherapy; 2018 Jan; 20(1):45-61. PubMed ID: 29079356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease.
    Xiong N; Yang H; Liu L; Xiong J; Zhang Z; Zhang X; Jia M; Huang J; Zhang Z; Mohamed AA; Lin Z; Wang T
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):411-422. PubMed ID: 23770451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Effect of Human Umbilical Cord Mesenchymal Stromal Cells in Protection of Dopaminergic Neurons from Apoptosis by Reducing Oxidative Stress in the Early Stage of a 6-OHDA-Induced Parkinson's Disease Model.
    Chi H; Guan Y; Li F; Chen Z
    Cell Transplant; 2019 Dec; 28(1_suppl):87S-99S. PubMed ID: 31775521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
    Xue YQ; Zhao LR; Guo WP; Duan WM
    Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neural stem cells transplantation combined with ethyl stearate improve PD rats motor behavior by promoting NSCs migration and differentiation.
    Huang J; Yi L; Yang X; Zheng Q; Zhong J; Ye S; Li X; Li H; Chen D; Li C
    CNS Neurosci Ther; 2023 Jun; 29(6):1571-1584. PubMed ID: 36924304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dissociation between dopaminergic response and motor behavior following intrastriatal, but not intravenous, transplant of bone marrow mononuclear stem cells in a mouse model of Parkinson's disease.
    Calice da Silva C; Azevedo BN; Machado DC; Zimmer ER; Martins LAM; da Costa JC
    Behav Brain Res; 2017 May; 324():30-40. PubMed ID: 28167338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
    Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
    Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
    Park HJ; Lim S; Joo WS; Yin CS; Lee HS; Lee HJ; Seo JC; Leem K; Son YS; Kim YJ; Kim CJ; Kim YS; Chung JH
    Exp Neurol; 2003 Mar; 180(1):93-8. PubMed ID: 12668152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
    Guo X; Liu T; Zhao D; Wang X; Liu D; He Y; Shan C; Kong Y; Hu W; Tao B; Sun L; Zhao H; Li S; Liu J
    Neuroscience; 2017 Jul; 356():229-241. PubMed ID: 28504195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CART modulates the effects of levodopa in rat model of Parkinson's disease.
    Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
    Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.